DCGI granted Cipla regulatory approval to launch Favipiravir in the India, a drug to treat mild COVID symptoms. It will be launched under the brand Ciplenza with each tablet retailing at Rs.68. This is not Remdesivir, used for acute COVID symptoms. Favipiravir was developed by Fujifilm Toyama Chemical and used to treat common influenza.